Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis

Ernestina Saulle, Alessia Petronelli, Luca Pasquini, Eleonora Petrucci, Gualtiero Mariani, Mauro Biffoni, Gianluigi Ferretti, Giovanni Scambia, Pierluigi Benedetti-Panici, Francesco Cognetti, Robin Humphreys, Cesare Peschle, Ugo Testa

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

In the present study we have explored the sensitivity of ovarian cancer cells to TRAIL and proteasome inhibitors. Particularly, we have explored the capacity of proteasome inhibitors to bypass TRAIL resistance of ovarian cancer cells. For these studies we have used the A2780 ovarian cancer cell line and its chemoresistant derivatives A2780/DDP and A2780/ADR, providing evidence that: (i) the three cell lines are either scarcely sensitive (A2780 and A2780/ADR) or moderately sensitive (A2780/DDP) to the cytotoxic effects of TRAIL; (ii) the elevated c-FLIP expression observed in ovarian cancer cells is a major determinant of TRAIL resistance of these cells; (iii) proteasome inhibitors (PS-341 or MG132) are able to exert a significant pro-apoptotic effect and to greatly enhance the sensitivity of both chemosensitive and chemoresistant A2780 cells to TRAIL; (iv) proteasome inhibitors damage mitochondria through stabilization of BH3-only proteins, Bax and caspase activation and significantly enhance TRAIL-R2 expression; (v) TRAIL-R2, but not TRAIL-R1, mediates the apoptotic effects of TRAIL on ovarian cancer cells. Importantly, studies on primary ovarian cancer cells have shown that these cells are completely resistant to TRAIL and proteasome inhibitors markedly enhance the sensitivity of these cells to TRAIL. Given the high susceptibility of ovarian cancer cells to proteasome inhibitors, our results further support the experimental use of these compounds in the treatment of ovarian cancer.

Original languageEnglish
Pages (from-to)635-655
Number of pages21
JournalApoptosis
Volume12
Issue number4
DOIs
Publication statusPublished - Apr 2007

Fingerprint

Proteasome Inhibitors
Ovarian Neoplasms
Cells
Apoptosis
bcl-2-Associated X Protein
Mitochondria
Caspases
Cell Line
Stabilization
Chemical activation
Derivatives

Keywords

  • BH3 only proteins
  • Cell death receptos
  • Ovarian cancer
  • Protesome inhibitors
  • TRAIL

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Cell Biology

Cite this

Saulle, E., Petronelli, A., Pasquini, L., Petrucci, E., Mariani, G., Biffoni, M., ... Testa, U. (2007). Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis, 12(4), 635-655. https://doi.org/10.1007/s10495-006-0025-9

Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. / Saulle, Ernestina; Petronelli, Alessia; Pasquini, Luca; Petrucci, Eleonora; Mariani, Gualtiero; Biffoni, Mauro; Ferretti, Gianluigi; Scambia, Giovanni; Benedetti-Panici, Pierluigi; Cognetti, Francesco; Humphreys, Robin; Peschle, Cesare; Testa, Ugo.

In: Apoptosis, Vol. 12, No. 4, 04.2007, p. 635-655.

Research output: Contribution to journalArticle

Saulle, E, Petronelli, A, Pasquini, L, Petrucci, E, Mariani, G, Biffoni, M, Ferretti, G, Scambia, G, Benedetti-Panici, P, Cognetti, F, Humphreys, R, Peschle, C & Testa, U 2007, 'Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis', Apoptosis, vol. 12, no. 4, pp. 635-655. https://doi.org/10.1007/s10495-006-0025-9
Saulle E, Petronelli A, Pasquini L, Petrucci E, Mariani G, Biffoni M et al. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis. 2007 Apr;12(4):635-655. https://doi.org/10.1007/s10495-006-0025-9
Saulle, Ernestina ; Petronelli, Alessia ; Pasquini, Luca ; Petrucci, Eleonora ; Mariani, Gualtiero ; Biffoni, Mauro ; Ferretti, Gianluigi ; Scambia, Giovanni ; Benedetti-Panici, Pierluigi ; Cognetti, Francesco ; Humphreys, Robin ; Peschle, Cesare ; Testa, Ugo. / Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. In: Apoptosis. 2007 ; Vol. 12, No. 4. pp. 635-655.
@article{ad2d25c022564ff5ad8560628779c9bc,
title = "Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis",
abstract = "In the present study we have explored the sensitivity of ovarian cancer cells to TRAIL and proteasome inhibitors. Particularly, we have explored the capacity of proteasome inhibitors to bypass TRAIL resistance of ovarian cancer cells. For these studies we have used the A2780 ovarian cancer cell line and its chemoresistant derivatives A2780/DDP and A2780/ADR, providing evidence that: (i) the three cell lines are either scarcely sensitive (A2780 and A2780/ADR) or moderately sensitive (A2780/DDP) to the cytotoxic effects of TRAIL; (ii) the elevated c-FLIP expression observed in ovarian cancer cells is a major determinant of TRAIL resistance of these cells; (iii) proteasome inhibitors (PS-341 or MG132) are able to exert a significant pro-apoptotic effect and to greatly enhance the sensitivity of both chemosensitive and chemoresistant A2780 cells to TRAIL; (iv) proteasome inhibitors damage mitochondria through stabilization of BH3-only proteins, Bax and caspase activation and significantly enhance TRAIL-R2 expression; (v) TRAIL-R2, but not TRAIL-R1, mediates the apoptotic effects of TRAIL on ovarian cancer cells. Importantly, studies on primary ovarian cancer cells have shown that these cells are completely resistant to TRAIL and proteasome inhibitors markedly enhance the sensitivity of these cells to TRAIL. Given the high susceptibility of ovarian cancer cells to proteasome inhibitors, our results further support the experimental use of these compounds in the treatment of ovarian cancer.",
keywords = "BH3 only proteins, Cell death receptos, Ovarian cancer, Protesome inhibitors, TRAIL",
author = "Ernestina Saulle and Alessia Petronelli and Luca Pasquini and Eleonora Petrucci and Gualtiero Mariani and Mauro Biffoni and Gianluigi Ferretti and Giovanni Scambia and Pierluigi Benedetti-Panici and Francesco Cognetti and Robin Humphreys and Cesare Peschle and Ugo Testa",
year = "2007",
month = "4",
doi = "10.1007/s10495-006-0025-9",
language = "English",
volume = "12",
pages = "635--655",
journal = "Apoptosis : an international journal on programmed cell death",
issn = "1360-8185",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis

AU - Saulle, Ernestina

AU - Petronelli, Alessia

AU - Pasquini, Luca

AU - Petrucci, Eleonora

AU - Mariani, Gualtiero

AU - Biffoni, Mauro

AU - Ferretti, Gianluigi

AU - Scambia, Giovanni

AU - Benedetti-Panici, Pierluigi

AU - Cognetti, Francesco

AU - Humphreys, Robin

AU - Peschle, Cesare

AU - Testa, Ugo

PY - 2007/4

Y1 - 2007/4

N2 - In the present study we have explored the sensitivity of ovarian cancer cells to TRAIL and proteasome inhibitors. Particularly, we have explored the capacity of proteasome inhibitors to bypass TRAIL resistance of ovarian cancer cells. For these studies we have used the A2780 ovarian cancer cell line and its chemoresistant derivatives A2780/DDP and A2780/ADR, providing evidence that: (i) the three cell lines are either scarcely sensitive (A2780 and A2780/ADR) or moderately sensitive (A2780/DDP) to the cytotoxic effects of TRAIL; (ii) the elevated c-FLIP expression observed in ovarian cancer cells is a major determinant of TRAIL resistance of these cells; (iii) proteasome inhibitors (PS-341 or MG132) are able to exert a significant pro-apoptotic effect and to greatly enhance the sensitivity of both chemosensitive and chemoresistant A2780 cells to TRAIL; (iv) proteasome inhibitors damage mitochondria through stabilization of BH3-only proteins, Bax and caspase activation and significantly enhance TRAIL-R2 expression; (v) TRAIL-R2, but not TRAIL-R1, mediates the apoptotic effects of TRAIL on ovarian cancer cells. Importantly, studies on primary ovarian cancer cells have shown that these cells are completely resistant to TRAIL and proteasome inhibitors markedly enhance the sensitivity of these cells to TRAIL. Given the high susceptibility of ovarian cancer cells to proteasome inhibitors, our results further support the experimental use of these compounds in the treatment of ovarian cancer.

AB - In the present study we have explored the sensitivity of ovarian cancer cells to TRAIL and proteasome inhibitors. Particularly, we have explored the capacity of proteasome inhibitors to bypass TRAIL resistance of ovarian cancer cells. For these studies we have used the A2780 ovarian cancer cell line and its chemoresistant derivatives A2780/DDP and A2780/ADR, providing evidence that: (i) the three cell lines are either scarcely sensitive (A2780 and A2780/ADR) or moderately sensitive (A2780/DDP) to the cytotoxic effects of TRAIL; (ii) the elevated c-FLIP expression observed in ovarian cancer cells is a major determinant of TRAIL resistance of these cells; (iii) proteasome inhibitors (PS-341 or MG132) are able to exert a significant pro-apoptotic effect and to greatly enhance the sensitivity of both chemosensitive and chemoresistant A2780 cells to TRAIL; (iv) proteasome inhibitors damage mitochondria through stabilization of BH3-only proteins, Bax and caspase activation and significantly enhance TRAIL-R2 expression; (v) TRAIL-R2, but not TRAIL-R1, mediates the apoptotic effects of TRAIL on ovarian cancer cells. Importantly, studies on primary ovarian cancer cells have shown that these cells are completely resistant to TRAIL and proteasome inhibitors markedly enhance the sensitivity of these cells to TRAIL. Given the high susceptibility of ovarian cancer cells to proteasome inhibitors, our results further support the experimental use of these compounds in the treatment of ovarian cancer.

KW - BH3 only proteins

KW - Cell death receptos

KW - Ovarian cancer

KW - Protesome inhibitors

KW - TRAIL

UR - http://www.scopus.com/inward/record.url?scp=33947141832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947141832&partnerID=8YFLogxK

U2 - 10.1007/s10495-006-0025-9

DO - 10.1007/s10495-006-0025-9

M3 - Article

C2 - 17252198

AN - SCOPUS:33947141832

VL - 12

SP - 635

EP - 655

JO - Apoptosis : an international journal on programmed cell death

JF - Apoptosis : an international journal on programmed cell death

SN - 1360-8185

IS - 4

ER -